The 2025 Norway Life Sciences Trend Analysis offers a comprehensive overview of one of Scandinavia’s most promising innovation hubs. With 531 active life science companies — including 179 biotech firms and 90 digital health players — Norway continues to strengthen its role in the Nordic life science landscape.
This year’s report highlights a notable concentration in biotech R&D and therapeutic development, with oncology, infectiology, and endocrinology leading the clinical pipeline. Despite a dip in overall financing compared to neighboring countries, Norway still achieved standout deals such as Calluna Pharma’s USD 82 million Series A round, reinforcing investor confidence in homegrown innovation.
The report also includes comparative benchmarks with Denmark, Finland, and Sweden, offering valuable insights for companies seeking to understand Norway’s strategic position within the broader Nordic ecosystem.
For more insights, request a free Biotechgate demo.